External validation of a novel HR-pQCT fracture risk assessment tool (μFRAC) in a female cohort: Sahlgrenska University Hospital Prospective Evaluation of Risk of Bone Fractures (SUPERB) study

在女性队列中对新型高分辨率外周定量CT骨折风险评估工具(μFRAC)进行外部验证:萨尔格伦斯卡大学医院骨折风险前瞻性评估(SUPERB)研究

阅读:2

Abstract

The Microarchitecture Fracture Risk Assessment Calculator ([Formula: see text]FRAC) was developed to predict osteoporotic fracture risk using direct measures of bone microarchitecture. However, its performance has not yet been externally validated in women. This study aims to evaluate the performance of the [Formula: see text]FRAC model in predicting osteoporotic fracture risk in a cohort of older women. The performance of [Formula: see text]FRAC was assessed in a population of 2307 postmenopausal women aged 75-80 yr in Gothenburg, Sweden. All participants underwent HR-pQCT scanning of the distal radius and distal tibia (82 [Formula: see text]m). Incident fracture information was collected from regional X-ray archives up until March 2023. The [Formula: see text]FRAC 5- and 10-yr risk of major osteoporotic fracture (MOF) and any osteoporotic fracture were calculated for all participants. The model discrimination was assessed using receiver operator characteristic (ROCs) curves and area under the curve (AUCs). FRAX and femoral neck areal bone mineral density (FN aBMD) were used as reference models for comparison. During the follow-up period (mean 6.82 [Formula: see text] 2.48 yr), 584 participants (25.3%) sustained an MOF. The AUCs for MOF models for 5- and 10-yr predictions were similar for [Formula: see text]FRAC (AUC = 0.601-0.634) compared with reference models of FRAX (AUC = 0.615-0.618) and FN aBMD (AUC = 0.596). Overall, [Formula: see text]FRAC showed good generalizability (regression slope 0.82-1.00) to the external cohort. Fracture risk prediction by [Formula: see text]FRAC was demonstrated to perform consistently with FRAX and FN aBMD in this external cohort of elderly females, suggesting it is a viable alternative fracture risk prediction tool. A benefit of [Formula: see text]FRAC is that it is based on bone microarchitecture rather than binary clinical risk factors, so it has potential to be sensitive to changes in bone fragility as a function of age-related deterioration or anti-osteoporosis treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。